Akoya Biosciences Strengthens Leadership Team with Spatial Biology and Molecular Pathology Experts

Akoya names Niro Ramachandran, Ph.D. as Chief Business Officer and Gavin Gordon, Ph.D. as Vice President of Clinical Market Development.

MENLO PARK, Calif. — September 2, 2020 Akoya Biosciences, Inc., The Spatial Biology Company™, today announced the expansion of its leadership team with the appointment of two senior leaders with expertise in spatial biology and molecular pathology. Niro Ramachandran, Ph.D. a widely respected senior business leader with extensive experience in spatial genomics, has been appointed Chief Business Officer at Akoya. Gavin Gordon, Ph.D. has joined Akoya as VP of Clinical Market Development, bringing expertise in cancer diagnostics, translational research and partnerships with pharma and biotech companies.

In his new role, Dr. Ramachandran is responsible for developing a robust roadmap and commercialization strategy for Akoya’s platforms. His leadership will help Akoya maximize their industry-leading spatial analysis platforms and construct a state-of-the-art spatial biology ecosystem. Prior to joining Akoya, Dr. Ramachandran built and led the spatial genomics business at NanoString. He holds a Ph.D. in biochemistry from the University of Windsor. Before entering the industry, he was a scientist at Harvard Medical School.

“Akoya has the largest portfolio of spatial biology solutions in the industry, and its innovative platforms have been widely cited in a variety of peer-reviewed publications for biomarker discovery and translational research,” said Niro Ramachandran, Chief Business Officer, Akoya Biosciences. “I am excited to join Akoya at this critical point in its journey to transform discovery and clinical research with the true power of spatial biology.”

In his new role, Dr. Gordon is responsible for developing and expanding partnerships with biopharmaceutical companies and leading academic institutions to advance the use of Akoya’s platforms in translational and clinical research. Prior to joining Akoya, Dr. Gordon held senior level positions at Fluidigm and Thermo Fisher Scientific and has significant commercial and clinical market development experience. He holds a Ph.D. in molecular pathology from the University of North Carolina. He has also served as Assistant Professor at Harvard Medical School and as a faculty member of Brigham and Women’s Hospital and Dana-Farber/Harvard Cancer Center.

“Akoya is uniquely positioned to power the discovery and validation of next-generation spatial biology biomarkers that will ultimately improve how cancer and other debilitating diseases are diagnosed and treated,” said Gavin Gordon, VP of Clinical Market Development, Akoya Biosciences. “Akoya’s industry leading suite of solutions will broadly support physicians and researchers and enable patients to more fully realize the promise of a precision medicine approach to clinical treatment planning, particularly for immuno-oncology where the spatial context of biomarkers is essential. I’m thrilled to have the opportunity to leverage Akoya’s platforms to advance clinical and translational research and drive meaningful improvements in patient care.”

Brian McKelligon, CEO of Akoya Biosciences, said, “We are truly honored that Niro and Gavin elected Akoya as the next phase of their incredible careers. Their collective experience and expertise will be vital to Akoya’s continuing leadership in the rapidly expanding spatial biology market.”

About Akoya Biosciences
Akoya Biosciences, The Spatial Biology Company™, offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has two industry-leading platforms that empower investigators and researchers to gain a deeper understanding of complex diseases such as cancer, and other immune system or neurological disorders. The CODEX® system is the only benchtop platform that can efficiently quantify more than 40 biomarkers and is ideally suited for biomarker discovery. The Phenoptics™ platform is the only end-to-end multiplexed immunofluorescence solution with the robustness and high throughput necessary for translational research and clinical trials. For more information, please visit https://www.akoyabio.com/.

Media Contact:
Michelle Linn
Bioscribe, Inc.
774-696-3803
michelle@bioscribe.com

Cloud-Based Image Analysis and Collaboration is Here.

X